Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Tetsuya SakaiHibiki UdagawaShingo MatsumotoKiyotaka YohKaname NosakiTakaya IkedaYoshitaka ZenkeKeisuke KiritaSeiji NihoTetsuo AkimotoKoichi GotoGenichiro IshiiPublished in: Journal of cancer research and clinical oncology (2020)
Absence of definitive morphological features in a biopsy sample could be a useful predictor of the efficacy of pembrolizumab in NSq NSCLC patients with tumor PD-L1 scores ≥ 50%, as these tumors are likely to show high tumor PD-L1 expression and high TMB.